University Health Network

The Ontario Cancer Institute

Amgen Canada Inc.

Amgen Inc.

Other

Hospital for Special Surgery

Casi Pharmaceuticals, Inc.

Tak Wah Mak

Michael W Tusche

Karl Lang

Pamela S Ohashi

Philipp Lang

Dirk Brenner

Gloria Lin

Steven Kiyoshi Yoshinaga

Giorgio Senaldi

Mark R Bray

Jacqueline M Mason

Graham Fletcher

Arda Shahinian

Anna Tafuri Bladt

Ursula Kapp

Tadatsugu Taniguchi

Craig B Thompson

Guohua Pan

Josef Martin Penninger

Yi Yao

Carl Peter Blobel

Armin Reitmair

Brian Hershenfield

Woong-Kyung Suh

Thorsten Maretzky

Kenji Kishihara

David McIlwain

Haruhiko Suzuki

Xiuqiu Lai

David Peter Siderovski

Luc Edgar Marengere

Gordon Stuart Duncan

Paul David Waterhouse

Kathrin Zaugg

Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

Combination therapies for inhibition of polo-like kinase 4

Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

Combination therapies for inhibition of TTK protein kinase

The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.

Methods and compositions for modulating toso activity

The present invention is directed to methods and compositions for identifying targets for induction of self-tolerance and treatment of autoimmune disease.

Methods and compositions for detection of targets for autoimmune disease

Disclosed are methods for treating a subject with an EGFR dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent ('First Agent') that decreases the biological activity of iRhom1 and an effective amount of an agent ('Second Agent') that decreases the biological activity of iRhom2. Alternatively, the method comprises the step of administering to the subject an effective amount of an agent (&#x201c;First Agent&#x201d;) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (&#x201c;Second Agent&#x201d;) that modulates formation of a complex between TACE and iRhom2. Also disclosed are assays for identifying such agents.

Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2

Methods and compositions for modulating Toso activity

The present invention provides methods and compositions for modulating Toso activity and treating diseases and disorders in which Toso is implicated. Such methods and compositions include the use of one or more antibodies that bind to a Toso protein or to a ligand of a Toso protein.

Antibodies to Toso

A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of 2ME2 or a derivative thereof.

Method for the treatment of multiple sclerosis

Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.

Polypeptides involved in immune response

The present invention provides B7 Related Protein-2 (B7RP-2) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7RP-2 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7RP-2 polypeptides.

Downregulation of immune response by administering B7RP-2 fusion protein

Materials and methods are disclosed for modulating proliferation of cell types associated with Hodgkin's disease through inhibition of IL-13 and components in IL-13 associated signal transduction pathways. Methods to identify inhibitors, compositions comprising the inhibitors, and methods using the inhibitors to treat Hodgkin's disease are also disclosed.

Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth

Growing community of inventors

Toronto, Canada

Tak Wah Mak